TEZSPIRE Asthma Japan Post-Marketing Study (PMS)

Study identifier:D5180C00034

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Will Be Recruiting

Official Title

TEZSPIRE Subcutaneous Injection 210mg Specific use-results study (Long term) in patients with Bronchial asthma.

Medical condition

Bronchial asthma (only the patients with severe or intractable bronchial asthma which could not be controlled with the existing therapy)

Phase

N/A

Healthy volunteers

Study drug

Sex

All

Estimated Enrollment

400

Study type

Observational

Age

n/a - n/a

Date

Study Start Date: 01 Mar 2023

Estimated Primary Completion Date: 16 Nov 2029

Estimated Study Completion Date: 16 Nov 2029

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Feb 2023 by AstraZeneca

Collaborators

Inclusion and exclusion criteria

No locations available

Arms	Assigned Interventions

Documents available

Trial Results Summaries
Available here

Contacts

Contact

AstraZeneca Clinical Study Information Center

1-877-240-9479

[email protected]

Investigators

Principal Investigator

Toshimitsu Tokimoto

AstraZeneca KK